Lessons from an unfavorable genetics therapy test for Duchenne muscle dystrophy

.Nature Medication, Posted online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec received FDA permission after a damaging trial, which highlights the various difficulties as well as obstacles of medication growth in this setting.